This Article Full Text (PDF) All Versions of this Article: 1533317508320603v1 23/6/593    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Tangwongchai, S. Articles by Chankrachang, S. Search for Related Content PubMed PubMed Citation Articles by Tangwongchai, S. Articles by Chankrachang, S. Social Bookmarking                         What's this?

Galantamine for the Treatment of BPSD in Thai Patients With Possible Alzheimer's Disease With or Without Cerebrovascular Disease

Department of Psychiatry, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok Thailand, sookjaroen{at}gmail.com

N. Thavichachart, MD

Department of Psychiatry, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok Thailand

V. Senanarong, MD

Division of Neurology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok Thailand

N. Poungvarin, MD

Division of Neurology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok Thailand

K. Phanthumchinda, MD

Division of Neurology Faculty of Medicine, Chulalongkorn University, Bangkok

R. Praditsuwan, MD

Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok

S. Nidhinandana, MD

Department of Medicine, College of Medicine, Pramongkutklao Hospital Bangkok

S. Chankrachang, MD

Division of Neurolugy, Faculty of Medicine, Chiangmai University, Chiangmai

Objectives. This study was to investigate an efficacy of galantamine in treatment of behavioral and psychological symptoms of dementia in Thai elderly who suffered from possible Alzheimer's disease (AD) with or without cerebrovascular disease and vascular dementia.

Methods. A 6-month, multicenter, open-label, uncontrolled trial was undertaken in 75 patients. Eligible patients received an initial galantamine dose of 8 mg/dayand escalated over 5 to 8 weeks to maintenance doses of 16 or 24 mg/day. The behavioral response was assessed as an intention-to-treat analysis using the Behavioral Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD).

Results. Galantamine improved behavioral and psychological symptoms of dementia (P < .05 vs baseline) over the 24 weeks of treatment. BEHAVE-AD score was significantly improved from baseline in paranoid and delusion ideation, diurnal rhythm disturbances, anxieties, and phobias.

Conclusions. Galantamine may be a well-tolerated and effective treatment option for improving psychotic, behavioral, and psychological symptoms in Thai elderly with possible AD with or without cerebrovascular disease and vascular dementia.

Key Words: galantamine • BPSD • Alzheimer's disease • cerebrovascular disease • vascular dementia

This version was published on January 1, 2009

American Journal of Alzheimer's Disease and Other Dementias®, Vol. 23, No. 6, 593-601 (2009)
DOI: 10.1177/1533317508320603


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?